Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
R
RAD
vs
S
S&P/ASX 300
Over the past 12 months, RAD has underperformed S&P/ASX 300, delivering a return of -79% compared to S&P/ASX 300's 1% drop.
Stocks Performance
RAD vs S&P/ASX 300
Performance Gap
RAD vs S&P/ASX 300
Performance By Year
RAD vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Radiopharm Theranostics Ltd
Glance View
Radiopharm Theranostics is a biopharmaceutical company that develops radiopharmaceutical drugs for cancer. These medicines use a radioactive component to help doctors locate tumors with imaging or deliver radiation directly to cancer cells. The company is building a pipeline of diagnostic and therapeutic products rather than selling a broad commercial drug portfolio today. Its main customers are hospitals, cancer specialists, and ultimately patients, through approved medical treatments. In the business model, value comes from advancing drug candidates through clinical development, securing regulatory approvals, and then partnering with larger drug makers or selling the medicines through healthcare channels. It may also earn money from licensing and collaboration deals tied to its drug programs. What makes the business different is that it sits at the intersection of imaging and treatment. Instead of treating cancer with a one-size-fits-all drug, Radiopharm focuses on finding tumors with precision and then targeting them with radiation-based therapies. That makes it part of a specialized corner of oncology where the science, manufacturing, and regulatory path are all closely linked.